

The HA Drug Advisory Committee (DAC), comprising doctors, clinical pharmacologists and pharmacists, systematically appraises new drugs every three months. DAC is supported by expert panels which provide specialist views on the selection of drugs for individual specialties.

Drug Advisory Committee August 2025 Meeting Outcome

	Generic / Brand name	Meeting outcome	Primary reason for unsuccessful application ¹
1	Apalutamide (Erleada)	Unsuccessful	The justification of the treatment's cost in relation to its benefits is insufficient
2	Asciminib (Scemblix)	Approved	
3	Atezolizumab (Tecentriq)	Approved	
4	Daratumumab/Lenalidomide (Darzalex/Revlimid)	Pending	Pending further information
5	Dostarlimab (Jemperli)	Unsuccessful	
6	Durvalumab (Imfinzi)	Approved	
7	Eladocogene exuparvovec (Upstaza)	Pending	Pending further information
8	Elranatamab (Elrexfio)	Approved	
9	Enzalutamide (Xtandi)	Unsuccessful	The justification of the treatment's cost in relation to its benefits is insufficient
10	Eravacycline (Xerava)	Unsuccessful	Alternative(s) available in HADF with comparable benefits
11	Etanercept Biosimilar (Erelzi)	Pending	Pending further information
12	Fenfluramine (Fintepla)	Unsuccessful	The justification of the treatment's cost in relation to its benefits is insufficient
13	Gilteritinib (Xospata)	Approved	
14	Maralixibat (Livmarli)	Unsuccessful	The justification of the treatment's cost in relation to its benefits is insufficient
15	Nirsevimab (Beyfortus)	Pending	Pending further information
16	Nivolumab (Opdivo)	Approved	
17	Nivolumab/Ipilimumab (Opdivo/Yervoy)	Approved	
18	Olaparib (Lynparza)	Unsuccessful	
19	Pembrolizumab/Lenvatinib/ (Keytruda/Lenvima)	Unsuccessful	
20	Ravulizumab (Ultomiris)	Approved	

	Generic / Brand name	Meeting outcome	Primary reason for unsuccessful application¹
21	Roxadustat (Evrenzo)	Approved	
22	Rurioctocog alfa pegol (Adynovate)	Unsuccessful	Alternative(s) available in HADF with comparable benefits
23	Secukinumab (Cosentyx)	Approved	
24	Solriamfetol (Sunosi)	Unsuccessful	The justification of the treatment's cost in relation to its benefits is insufficient
25	Spesolimab (Spevigo)	Unsuccessful	The justification of the treatment's cost in relation to its benefits is insufficient / Alternative(s) available in HADF with comparable benefits
26	Tazemetostat (Tazverik)	Unsuccessful	The justification of the treatment's cost in relation to its benefits is insufficient
27	Tirzepatide (Mounjaro)	Unsuccessful	The justification of the treatment's cost in relation to its benefits is insufficient / Major budget impact
28	Tislelizumab (Tevimbra)	Unsuccessful	Insufficient evidence to demonstrate significant clinical benefits in the proposed targeted patient population
29	Toripalimab (Loqtorzi)	Approved	
30	Ustekinumab Biosimilar (Wezlana)	Pending	Pending further information
31	Velmanase alfa (Lamzede)	Approved	
32	Venetoclax (Venclexta)/Rituximab	Approved	
33	Vutrisiran (Amvuttra)	Unsuccessful	The justification of the treatment's cost in relation to its benefits is insufficient
34	Zanubrutinib (Brukinsa)	Approved	

¹ The evaluation embraces the principles of safety, efficacy and cost-effectiveness and takes into account other relevant factors, including international recommendations and practices, advance in technology, disease state, patient compliance, quality of life, actual experience in the use of drugs as well as views of professionals and patients groups.